Search Result

Results for "

oligomerization

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AIM2 (1) Amyloid-β (4) Apoptosis (7) Atg8/LC3 (1) Autophagy (1) Bacterial (1) Bcl-2 Family (3) Caspase (1) Cholinesterase (ChE) (2) COMT (3) Drug Metabolite (1) Dynamin (1) HIV (1) HIV Integrase (1) IRE1 (4) Isotope-Labeled Compounds (2) Mixed Lineage Kinase (2) Necroptosis (1) NEKs (1) NOD-like Receptor (NLR) (8) p62 (1) Pyroptosis (2) RAD51 (1) RIP kinase (3) STING (1) Tau Protein (2) VDAC (2) α-synuclein (2)
By Research Areas:	Cancer (16) Cardiovascular Disease (3) Infection (2) Inflammation/Immunology (9) Metabolic Disease (2) Neurological Disease (15)

By Targets:

AIM2 (1)

Amyloid-β (4)

Apoptosis (7)

Atg8/LC3 (1)

Autophagy (1)

Bacterial (1)

Bcl-2 Family (3)

Caspase (1)

Cholinesterase (ChE) (2)

COMT (3)

Drug Metabolite (1)

Dynamin (1)

HIV (1)

HIV Integrase (1)

IRE1 (4)

Isotope-Labeled Compounds (2)

Mixed Lineage Kinase (2)

Necroptosis (1)

NEKs (1)

NOD-like Receptor (NLR) (8)

p62 (1)

Pyroptosis (2)

RAD51 (1)

RIP kinase (3)

STING (1)

Tau Protein (2)

VDAC (2)

α-synuclein (2)

By Research Areas:

Cancer (16)

Cardiovascular Disease (3)

Infection (2)

Inflammation/Immunology (9)

Metabolic Disease (2)

Neurological Disease (15)

Inhibitors & Agonists

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145580

Minzasolmin

UCB0599; (R)-NPT200-11
α-synuclein Neurological Disease

Minzasolmin is an alpha-synuclein oligomerization inhibitor .

Minzasolmin UCB0599; (R)-NPT200-11	α-synuclein	Neurological Disease
Minzasolmin is an alpha-synuclein oligomerization inhibitor .

HY-129122

VBIT-4 5+ Cited Publications	VDAC	Cardiovascular Disease Neurological Disease
VBIT-4 is an inhibitor of voltage-dependent anion channel 1 (VDAC1) oligomerization with a binding affinity (K_d) of 17 μM. VBIT-4, as an apoptosis inhibitor, can be used for therapeutic purposes in apoptosis-associated disorders, such as neurodegenerative and cardiovascular diseases .

HY-149237

hAChE-IN-2	Cholinesterase (ChE) Tau Protein	Neurological Disease
hAChE-IN-2 is a potent hAChE inhibitor, with an IC₅₀ of 0.71 μM. hAChE-IN-2 can also inhibits tau-oligomerization, with an EC₅₀ of 2.21 μM. hAChE-IN-2 exhibits neuroprotective activity .

HY-156179

DDC 2′,3′-O-disulfate	Amyloid-β	Neurological Disease
DDC 2′,3′-O-disulfate (compound 4) prevents the fibrillization and oligomerization of Aβ42. DDC 2′,3′-O-disulfate has the potential for Alzheimer's disease (AD) research .

HY-156180

DDC 3′-O-β-D glucuronide	Drug Metabolite	Neurological Disease
DDC 3′-O-β-D glucuronide (compound 5) is a drug metabolite that can prevent the fibrillization and oligomerization of Aβ42. DDC 3′-O-β-D glucuronide has potential for the research of Alzheimer's disease .

HY-17406S

Tolcapone-d7 Ro 40-7592 d₇	Isotope-Labeled Compounds COMT Amyloid-β	Neurological Disease
Tolcapone-d₇ is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells[1][2].

HY-161296

TH6342	Bacterial HIV	Infection
TH6342 is a SAMHD1 modulator that binds to pretetrameric SAMHD1 and prevents its oligomerization and allosteric activation. SAMHD1 is a dNTP triphosphohydrolase and an HIV-1 restriction factor. SAMHD1 can limit the replication of retroviruses and DNA viruses and has antiviral effects. The inhibitory mechanism of TH6342 does not occupy the SAMHD1 nucleotide-binding pocket, gently binds the target, and functions as a chemical probe .

HY-149604

NLRP3-IN-21	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-21 (compound L38) is a NLRP3 inflammasome inhibitor with inflammatory properties. NLRP3-IN-21 inhibits NLRP3 inflammasome activation and pyroptosis by suppressing gasdermin D cleavage, ASC oligomerization, and NLRP3 inflammasome assembly .

HY-156374

D359-0396	NOD-like Receptor (NLR) Pyroptosis	Inflammation/Immunology
D359-0396 is an orally active NLRP3 inflammasome inhibitor. D359-0396 inhibits pyroptosis and IL-1β release in macrophages. D359-0396 also inhibits the oligomerization of NLRP3, ASC and the cleavage of GSDMD. D359-0396 alleviates EAE, and also improves survival after septic shock in mice .

HY-120079

MSN-125 1 Publications Verification	Bcl-2 Family Apoptosis	Cancer
MSN-125 is a potent Bax and Bak oligomerization inhibitor. MSN-125 prevents mitochondrial outer membrane permeabilization (MOMP) with an IC₅₀ of 4 μM. MSN-125 potently inhibits Bax/Bak-mediated apoptosis in HCT-116, BMK Cells, and primary cortical neurons, protects primary neurons against glutamate excitotoxicity .

HY-161242

CBI1	Bcl-2 Family	Cancer
CBI1 is a covalent BAX inhibitor. CBI1 selectively derivatizes BAX at C126 and inhibits BAX activation by triggering ligands or point mutagenesis. CBI1 blocks t-2-hex lipidation and oligomerization of BAX. CBI1 inhibits BAX activation induced by BH3 ligands, F116A mutagenesis or t-2-hex .

HY-136735

IRE1α kinase-IN-1	IRE1	Neurological Disease Cancer
IRE1α kinase-IN-1 is a highly selective IRE1α (ERN1) inhibitor, with an IC₅₀ of 77 nM. IRE1α kinase-IN-1 displays 100-fold selectivity for IRE1α over the IRE1β isoform. IRE1α kinase-IN-1 inhibits ER stress-induced IRE1α oligomerization and autophosphorylation, and also inhibits IRE1α RNase activity (IC₅₀=80 nM) .

HY-U00460

3,6-DMAD hydrochloride	IRE1	Cancer
3,6-DMAD hydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD hydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD hydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD hydrochloride can be used for research of cancer .

HY-U00460B

3,6-DMAD dihydrochloride	IRE1	Cancer
3,6-DMAD dihydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD dihydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD dihydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD dihydrochloride can be used for research of cancer .

HY-144226

NLRP3/AIM2-IN-3	NOD-like Receptor (NLR) AIM2 Pyroptosis	Inflammation/Immunology
NLRP3/AIM2-IN-3 (compound 59) is a potent inhibitor with differential species specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis. NLRP3/AIM2-IN-3 shows inhibitory efficacy against pyroptosis in THP-1 macrophages stimulated with LPS/nigericin, with an IC₅₀ of 0.077 ± 0.008 μM. NLRP3/AIM2-IN-3 disturbs the interaction of NLRP3 or AIM2 with the adaptor protein ASC and inhibited ASC oligomerization .

HY-108937

NSC 15364

5 Publications Verification

VDAC Apoptosis Cardiovascular Disease Neurological Disease

NSC 15364 is an inhibitor of VDAC1 oligomerization and apoptosis .
HY-145580A

(S)-Minzasolmin

(S)-UCB0599; (S)-NPT200-11
α-synuclein Neurological Disease

(S)-Minzasolmin is an isomer of minzasolmin (HY-145580), an inhibitor of α-synuclein oligomerization .

NSC 15364 5 Publications Verification	VDAC Apoptosis	Cardiovascular Disease Neurological Disease
NSC 15364 is an inhibitor of VDAC1 oligomerization and apoptosis .

(S)-Minzasolmin (S)-UCB0599; (S)-NPT200-11	α-synuclein	Neurological Disease
(S)-Minzasolmin is an isomer of minzasolmin (HY-145580), an inhibitor of α-synuclein oligomerization .

HY-118948

MSN-50	Bcl-2 Family	Neurological Disease
MSN-50 is a Bax and Bak oligomerization inhibitor. MSN-50 efficiently inhibits liposome permeabilization, prevents genotoxic cell death and promotes neuroprotection .

HY-101112

Okicenone
Okicenone is a Hu protein R (HuR) inhibitor. Okicenone inhibits HuR oligomerization, interferes with HuR RNA binding, HuR trafficking, cytokine expression and T-cell activation .

HY-18633

MDK83190	Apoptosis	Cancer
MDK83190 is a potent apoptosis activator, induces Apaf-1 oligomerization, increases procaspase-9 processing and subsequent caspase-3 activation in a cyto c-dependent Manner .

HY-100691

NOD-IN-1 Maximum Cited Publications 7 Publications Verification	NOD-like Receptor (NLR)	Inflammation/Immunology
NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2, with IC₅₀ of 5.74 μM and 6.45 μM, respectively.

HY-18937

WEHI-345 2 Publications Verification	RIP kinase	Cancer
WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC₅₀ of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation .

HY-103349

PETCM 1 Publications Verification	Caspase Apoptosis	Cancer
PETCM is an activator of caspase-3 and acts as an cytochrome c (cyto c)-dependent manner. PETCM promotes Apaf-1 oligomerization and induces cell apoptosis in HeLa cells .

HY-122671

OB-1	Others	Neurological Disease
OB-1 is a stomatin-like protein-3 (STOML3) oligomerization blocker. OB-1 is an effective inhibitor of the self-association of Stomatin, STOML1 and STOML2, but not podocin .

HY-149233

hAChE-IN-1	Cholinesterase (ChE) Tau Protein	Neurological Disease
hAChE-IN-1 (Compound 24) is a potent hAChE inhibitor with an IC₅₀ of 1.09 μM. hAChE-IN-1 inhibits *tau-oligomerization* with an EC₅₀ of 2.71 μM in cellular tau FRET assay .

HY-100112

WEHI-345 analog	RIP kinase	Others
WEHI-345 analog is the analog of WEHI-345. WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC₅₀ of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation .

HY-163358

SLC3037	NOD-like Receptor (NLR) NEKs	Cardiovascular Disease Neurological Disease Inflammation/Immunology
SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases .

HY-150147

CAM833	RAD51 Apoptosis	Cancer
CAM833 is a potent orthosteric inhibitor of the interaction between BRCA2 and RAD51 with a K_d of 366 nM against the ChimRAD51 protein. CAM833 also inhibits RAD51 oligomerization. CAM833 increases the progression of G2/M-arrested cells into apoptosis .

HY-123572

Bis-T-23 AG1717	Dynamin HIV Integrase	Infection Metabolic Disease Inflammation/Immunology
Bis-T-23 (AG1717), tyrphostin derivative, is an HIV-I integrase inhibitor. Bis-T-23 can promote actin-dependent dynamin oligomerization. Bis-T-23 can be used for the research of HIV and chronic kidney diseases (CKD) .

HY-W688687

XIE62-1004-A	Autophagy p62 Atg8/LC3	Others
XIE62-1004-A is an inducer of p62-LC3 interaction. XIE62-1004-A can bind to the ZZ-domain of p62, inducing p62 oligomerization and activating p62-dependent autophagy .

HY-17406

Tolcapone 1 Publications Verification Ro 40-7592	COMT Amyloid-β Apoptosis	Neurological Disease Cancer
Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC₅₀ of 773 nM in the liver . Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis . Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma .

HY-136555

GSK717 4 Publications Verification	NOD-like Receptor (NLR)	Inflammation/Immunology
GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC₅₀ of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells .

HY-18509

IRE1α kinase-IN-2	IRE1	Cancer
IRE1α kinase-IN-2 is a potent IRE1α kinase inhibitor, with an EC₅₀ of 0.82 μM. IRE1α kinase-IN-2 inhibits IRE1α kinase autophosphorylation (IC₅₀=3.12 μM). IRE1α kinase-IN-2 inhibits XBP1 mRNA splicing in the WT cell lines .

HY-17406S1

Tolcapone-d4 Ro 40-7592-d₄	Isotope-Labeled Compounds COMT Amyloid-β Apoptosis	Neurological Disease Cancer
Tolcapone-d₄ is the deuterium labeled Tolcapone. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver[1]. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis[2]. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma[3].

HY-100432

LOC14 2 Publications Verification
LOC14 is a potent Protein disulfide isomerase (PDI) inhibitor with EC₅₀ and K_d values of 500 nM and 62 nM, respectively. LOC14 exhibits high stability in mouse liver microsomes and blood plasma, low intrinsic microsome clearance, and low plasma-protein binding . LOC14 inhibits PDIA3 activity, decreases intramolecular disulfide bonds and subsequent oligomerization (maturation) of HA in lung epithelial cells .

HY-149393

RIPK3-IN-3	Mixed Lineage Kinase RIP kinase	Cancer
RIPK3-IN-3 (compound 20) is a selective inhibitor of RIP kinase RIPK3 (IC₅₀=10 nM). RIPK3 mediates the phosphorylation of Mixed Lineage Kinase (MLKL) and causes necroptosis, while RIPK3-IN-3 inhibits p-MLKL oligomerization and thereby inhibits necroptosis. RIPK3-IN-3 also downregulates CXCL5 secretion and inhibits AsPC-1 cell migration and invasion .

HY-157214

NVS-STG2	STING	Cancer
NVS-STG2 is a molecular glue that targets STING and activates STING-mediated immune signaling. NVS-STG2 induces higher-order oligomerization of human STING by binding to pockets between adjacent STING dimer transmembrane domains, effectively acting as a molecular glue. NVS-STGI enhances the activity of cGAMP by inducing the formation of more abundant and larger oligomers. NVS-STG2 produces antitumor activity in animal models .

HY-156119

MLKL-IN-6	Mixed Lineage Kinase Necroptosis	Metabolic Disease Cancer
MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects .

HY-161072

CSC-6	NOD-like Receptor (NLR)	Inflammation/Immunology
CSC-6 is a NLRP3 inhibitor. CSC-6 can significantly inhibit IL-1β secreted by PMATHP-1 cells with an IC₅₀ value of 2.3 μM. CSC-6 specifically binds NLRP3 and inhibits NLRP3 activation by blocking ASC oligomerization during NLRP3 assembly. CSC-6 effectively reduces the symptoms of NLRP3 overactivation-mediated sepsis and gout in mouse models .

HY-146034

NOD1/2 antagonist-1	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
NOD1/2 antagonist-1 (compound 36b) is a potent NOD1/2 (nucleotide-binding oligomerization domain-like receptor 1/2) dual antagonist, with IC₅₀ values of 1.13 (NOD1) and 0.77 μM (NOD2), respectively. NOD1/2 antagonist-1 has a acceptable T_1/2 (67.6 min). NOD1/2 antagonist-1 (compound 36b) can improve the antitumor efficacy of Paclitaxel (PTX) .

Tolcapone-d7
Tolcapone-d₇ is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells[1][2].

Tolcapone-d4
Tolcapone-d₄ is the deuterium labeled Tolcapone. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver[1]. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis[2]. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: